Lindbrook Capital’s Alaunos Therapeutics TCRT Stock Holding History

Lindbrook Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11	Closed	-$3K	–	2200
2021 Q3	$3K	Buy	+11	New	+$3.36K	﹤0.01%	1446

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lindbrook Capital's TCRT Position: Q4 2021 in Review

Lindbrook Capital sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 11 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in TCRT in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

Lindbrook Capital reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
Lindbrook Capital sold 11 Alaunos Therapeutics shares in Q4 2021, an estimated $3K.
Lindbrook Capital first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 1 quarter.
Lindbrook Capital's Alaunos Therapeutics position peaked at $3K in Q3 2021.
165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.